Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein.
about
Apolipoprotein(a) acts as a chemorepellent to human vascular smooth muscle cells via integrin αVβ3 and RhoA/ROCK-mediated mechanismsOxidized phospholipids and lipoprotein-associated phospholipase A2 as important determinants of Lp(a) functionality and pathophysiological roleClinical Relevance of Biomarkers of Oxidative StressHigh-density lipoprotein and 4F peptide reduce systemic inflammation by modulating intestinal oxidized lipid metabolism: novel hypotheses and review of literatureLipid peroxidation generates biologically active phospholipids including oxidatively N-modified phospholipidsGeneration and biological activities of oxidized phospholipidsPro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a).Circulating levels of plasminogen and oxidized phospholipids bound to plasminogen distinguish between atherothrombotic and non-atherothrombotic myocardial infarction.Changes in lipoprotein(a), oxidized phospholipids, and LDL subclasses with a low-fat high-carbohydrate dietImaging of oxidation-specific epitopes with targeted nanoparticles to detect high-risk atherosclerotic lesions: progress and future directionsThematic review series: systems biology approaches to metabolic and cardiovascular disorders. Lipidomics: a global approach to lipid analysis in biological systems.Increase in the oxidised low-density lipoprotein level by smoking and the possible inhibitory effect of statin therapy in patients with cardiovascular disease: a retrospective study.The Dynamics of Oxidized LDL during Atherogenesis.Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials.Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study.Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trialOxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events.Oxidized phospholipids are present on plasminogen, affect fibrinolysis, and increase following acute myocardial infarction.Peptide mimotopes of malondialdehyde epitopes for clinical applications in cardiovascular disease.Lipoprotein(a): Cellular Effects and Molecular MechanismsRelease and capture of bioactive oxidized phospholipids and oxidized cholesteryl esters during percutaneous coronary and peripheral arterial interventions in humans.Emerging applications for zebrafish as a model organism to study oxidative mechanisms and their roles in inflammation and vascular accumulation of oxidized lipidsDifferential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesionsReduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial resultsPopulation and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study.Acute and long-term effect of percutaneous coronary intervention on serially-measured oxidative, inflammatory, and coagulation biomarkers in patients with stable anginaMCP-1 binds to oxidized LDL and is carried by lipoprotein(a) in human plasma.Oxidation-specific biomarkers and risk of peripheral artery diseaseDeterminants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a).Lipoprotein(a): a promising marker for residual cardiovascular risk assessment.The role of innate immunity in atherogenesis.Antioxidant enzyme gene transfer for ischemic diseases.Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study.Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity.Oxidized low-density lipoprotein as a biomarker of in vivo oxidative stress: from atherosclerosis to periodontitisOxidized low-density lipoprotein as a biomarker of cardiovascular diseases.Serum bilirubin and lipoprotein-a: how are these associated with whole blood viscosity?Experimental Animal Models Evaluating the Causal Role of Lipoprotein(a) in Atherosclerosis and Aortic Stenosis.Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis.Malondialdehyde Epitopes as Targets of Immunity and the Implications for Atherosclerosis.
P2860
Q24294266-813A15B3-181C-47E3-A1E8-82521BD09F66Q26747100-91FD8B3D-7219-44D4-B15A-D353CA742595Q26785512-1EFA4A42-F1D3-4B1A-BA19-F27ED7A29458Q26996600-852D3344-FA38-4AB7-B2DA-63A44E6D5275Q28389004-FD6364B9-9DEB-4D70-A87A-B44A37D23BA2Q28389691-33CBD4DB-DE8C-4174-857F-87B7D52781DFQ33561072-8CE023E2-7DC8-4B74-BCE2-5DC46EF7161EQ33597486-F8600899-A92E-433E-ACF2-DE4932E9FBABQ34188087-BCCA2AF0-3D71-4061-B06A-542F36BF93B5Q34518372-C951A5C2-4D62-4DEF-A749-6B348C69E683Q34556407-248C1DED-3A6A-4663-9D1A-363C92A6CB1FQ35008152-801E3035-14BF-4EBE-B301-E993DFFE7D6BQ35024665-13AC63D3-B469-4422-8C83-D391D4BCF3C7Q35130714-B36E0E05-E6CB-4BE6-82C8-F6F7526D77FCQ35212898-AA76E41C-BC4C-4A22-B95A-0CC61FD80188Q35276226-1C704B21-37D9-4643-8A76-D45CF7081097Q35592510-D785A479-D166-4345-8C16-35EF74C675EAQ35905628-0B71E7E9-9899-4014-B1B2-C45C665433A1Q36020265-06F08864-774B-4FFD-8504-E8CEB3EB55C2Q36237559-5158E400-6915-4ACC-B5AA-0AF47B4485AAQ36239453-4C8BCAAE-1B3F-451F-9949-6309C0A462E8Q36252515-B053DF5B-18DA-4D60-B6A7-D46D15471DCEQ36387263-F11D28BF-6E16-4728-9FBD-216FD236129CQ36731776-047EF022-6477-4242-A108-1E14296C96FCQ36731797-566F72D3-BDFF-4B7B-AA51-D94C20D8CA3DQ36739679-C24C4C58-5669-489B-A604-10BD543B6BF1Q36920584-1B386CEB-A792-4B2B-9F9A-719B3972925CQ37131142-86876453-CCE1-438E-A7E4-F4A437E38DA0Q37163064-A826E5BD-59F6-4034-8CE3-63404173CFBBQ37285933-32BC29DE-1C5D-4429-B9AE-3D44002762F6Q37357462-01506783-9E04-423C-A974-63179CA967ABQ37398189-D0708E90-3AE9-4F13-84FD-0CD840D97669Q37434626-B1BCA893-248D-4F54-A11D-817C207EB1DBQ37830940-528B0B8C-DD9A-4C29-AC40-62F4B4780923Q38026551-91182FBF-90ED-41CD-8189-061B513EDFF3Q38299279-1A80E128-2BA4-4BBD-9F5D-C9D88AF05FEEQ38405238-E1C4B709-227A-408C-9B05-4E8F503D2B45Q38701405-290BF2D7-D518-4F38-8D18-05E6FDAD8B79Q38839978-E4B28F0A-80BB-49F5-ACAB-0B0D1EA71FA2Q38846881-0AE5311A-C2AE-4B69-A23F-DB1404045FD0
P2860
Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Percutaneous coronary interven ...... phospholipids and lipoprotein
@nl
Percutaneous coronary interven ...... dized low-density lipoprotein.
@en
type
label
Percutaneous coronary interven ...... phospholipids and lipoprotein
@nl
Percutaneous coronary interven ...... dized low-density lipoprotein.
@en
prefLabel
Percutaneous coronary interven ...... phospholipids and lipoprotein
@nl
Percutaneous coronary interven ...... dized low-density lipoprotein.
@en
P2093
P1433
P1476
Percutaneous coronary interven ...... dized low-density lipoprotein.
@en
P2093
Amit Segev
Bradley H Strauss
Brian Shortal
Elizabeth R Miller
Herbert K Lau
Kyoo-Rok Han
Linda K Curtiss
P304
P356
10.1161/01.CIR.0000130844.01174.55
P407
P577
2004-06-07T00:00:00Z